Trilaciclib Combined With Immunochemotherapy for R/M HNSCC

NCT07679997 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Head & Neck Squamous Cell Carcinoma

Interventions

DRUG: Trilaciclib

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University